XML 48 R35.htm IDEA: XBRL DOCUMENT
v3.21.2

Commitments and Contingencies (Details Narrative) - USD ($) |  |  |  |  |  |  |  |  | 1 Months Ended | 2 Months Ended | 3 Months Ended | 9 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
May 02, 2021 | Dec. 21, 2020 | Aug. 12, 2020 | Sep. 12, 2018 | Aug. 20, 2018 | Mar. 22, 2018 | Sep. 14, 2015 | Sep. 14, 2015 | Dec. 24, 2013 | Dec. 24, 2013 | Sep. 30, 2021 | Aug. 31, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development costs |  |  |  |  |  |  |  |  |  |  |  |  | $ 227,181 | $ 799,420 | $ 933,122 | $ 1,012,038
General and administrative costs |  |  |  |  |  |  |  |  |  |  |  |  | 1,010,539 | 802,273 | 3,762,373 | 1,350,201
GEIS [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amount related to milestone payment |  |  |  |  |  |  |  |  |  |  | $ 67,582 |  |  |  |  |
NDA Consulting Corp [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Agreement term |  |  |  |  |  |  |  |  | one-year periods |  |  |  |  |  |  |
Consulting and advisory fee |  |  |  |  |  |  |  |  |  | $ 4,000 |  |  | 4,000 | 4,000 | 12,000 | 12,000
City of Hope [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate commitments expected |  |  |  |  |  |  |  |  |  |  | 319,000 |  | 319,000 |  | 319,000 |
City of Hope [Member] | Health Care, Patient Service [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate commitments expected |  |  |  |  |  |  |  |  |  |  | 800,000 |  | 800,000 |  | 800,000 |
Collaboration Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Advance amount related to milestone payment |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 24,171 | 43,411
Research and development costs |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 155,053 |
Collaboration Agreement [Member] | GEIS [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate commitments expected |  |  |  |  |  |  |  |  |  |  | 4,348,000 |  | 4,348,000 |  | 4,348,000 |
Collaboration Agreement [Member] | BioPharmaWorks LLC [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consulting and advisory fee |  |  |  |  |  |  | $ 10,000 |  |  |  |  |  |  |  |  |
Reimbursed expense |  |  |  |  |  |  |  |  |  |  |  |  | 30,000 | 30,000 | 90,000 | 90,000
Stock options grant date fair value |  |  |  |  |  |  |  | $ 670,715 |  |  |  |  |  |  |  |
Collaboration Agreement [Member] | Moffitt Cancer Center and Research Institute Hospital Inc [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Advance amount related to milestone payment |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 10,643 | 17,693 | 36,008
Research and development costs |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 103,927 |
Clinical Trial Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate commitments expected, description |  |  |  |  |  |  |  |  |  |  |  |  |  |  | The Company’s aggregate commitments pursuant to the aforementioned clinical trial agreements, less amounts previously paid to date under these agreements, totaled approximately $4,950,000 as of September 30, 2021, consisting of approximately $4,348,000 relating to the GEIS clinical trial and approximately $602,000 relating to the Moffit clinical trial, which are expected to be incurred through December 31, 2025. |
Aggregate commitments expected |  |  |  |  |  |  |  |  |  |  | 4,950,000 |  | 4,950,000 |  | $ 4,950,000 |
Clinical Trial Agreement [Member] | Moffitt Cancer Center and Research Institute Hospital Inc [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate commitments expected |  |  |  |  |  |  |  |  |  |  | 602,000 |  | 602,000 |  | 602,000 |
Clinical Trial Agreement [Member] | City of Hope [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Advance amount related to milestone payment |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  | 309,509 |
Research and development costs |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 309,509 |
Aggregate commitments expected |  |  |  |  |  |  |  |  |  |  | 2,433,000 |  | 2,433,000 |  | 2,433,000 |
Other Clinical Agreements [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate commitments expected |  |  |  |  |  |  |  |  |  |  | 394,000 |  | 394,000 |  | 394,000 |
Other Clinical Agreements [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development costs |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 977,000 |
Work Order Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development costs |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 91,505 |
Aggregate commitments expected |  |  |  |  |  |  |  |  |  |  | 868,000 |  | 868,000 |  | 868,000 |
Work Order Agreement [Member] | City of Hope [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Advance amount related to milestone payment |  |  |  |  |  |  |  |  |  |  |  |  | 6,857 |  | 21,170 |
Aggregate commitments expected |  |  |  |  |  |  |  |  |  |  | $ 21,170 |  | 21,170 |  | 21,170 |
Work Order Agreement [Member] | Theradex Systems, Inc. [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development costs |  |  |  | $ 954,000 |  |  |  |  |  |  |  |  | 869 | 917 | 9,350 | 12,393
Material Transfer Agreement [Member] | INSERM [Member] | Maximum [Member] | Development Milestones [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments |  |  |  |  |  | $ 1,750,000 |  |  |  |  |  |  |  |  |  |
Material Transfer Agreement [Member] | INSERM [Member] | Maximum [Member] | Commercial Milestones [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments |  |  |  |  |  | $ 6,500,000 |  |  |  |  |  |  |  |  |  |
Exclusive License Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amount charges to operations |  |  |  |  |  |  |  |  |  |  |  |  | 6,301 | $ 6,301 | 18,698 | $ 18,699
Exclusive License Agreement [Member] | First Four Years [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Minimum payments for royalties |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 50,000 |
Exclusive License Agreement [Member] | Five Years And Thereafter [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Minimum payments for royalties |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 100,000 |
Exclusive License Agreement [Member] | Moffitt Cancer Center and Research Institute Hospital Inc [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable license issue fee |  |  |  |  | $ 25,000 |  |  |  |  |  |  |  |  |  |  |
Annual license maintenance fee |  |  |  |  | 25,000 |  |  |  |  |  |  |  |  |  |  |
Payments on non-refundable milestone |  |  |  |  | $ 1,897,000 |  |  |  |  |  |  |  |  |  |  |
Percentage of milestone |  |  |  |  | 40.00% |  |  |  |  |  |  |  |  |  |  |
Employment Agreement [Member] | Dr. John Kovach [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual salary |  |  |  |  |  |  |  |  |  |  |  | $ 640,000 |  |  |  |
Employment Agreement [Member] | Dr.James [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual compensation | $ 775,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Master Service Agreement [Member] | Foundation for Angelman Syndrome Therapy [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of proceeds agree to pay under agreement |  |  | 500.00% |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum amount received under agreement |  |  | $ 250,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Service Agreement [Member] | IRTH Communications, LLC [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consulting and advisory fee |  | $ 7,500 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stock options grant date fair value |  | $ 100,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
General and administrative costs |  |  |  |  |  |  |  |  |  |  |  |  | $ 22,500 |  | $ 67,500 |

X
- Definition Advance amount related to milestone payment. + References No definition available. + Details
Name: | LIXT_AdvanceAmountRelatedToMilestonePayment
Namespace Prefix: | LIXT_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Agreement for a term. + References No definition available. + Details
Name: | LIXT_AgreementTermDescription
Namespace Prefix: | LIXT_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount charge to operations. + References No definition available. + Details
Name: | LIXT_AmountChargeToOperations
Namespace Prefix: | LIXT_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount related to milestone payment. + References No definition available. + Details
Name: | LIXT_AmountRelatedToMilestonePayment
Namespace Prefix: | LIXT_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Company is obligated to pay annual license maintenance fee.. + References No definition available. + Details
Name: | LIXT_AnnualLicenseMaintenanceFee
Namespace Prefix: | LIXT_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Consulting and advisory quarterly cash fee. + References No definition available. + Details
Name: | LIXT_ConsultingAndAdvisoryCashFee
Namespace Prefix: | LIXT_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Maximum amount received under agreement. + References No definition available. + Details
Name: | LIXT_MaximumAmountReceivedUnderAgreement
Namespace Prefix: | LIXT_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestone payments. + References No definition available. + Details
Name: | LIXT_MilestonePayments
Namespace Prefix: | LIXT_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Company is obligated to pay non refundable license issue fee.. + References No definition available. + Details
Name: | LIXT_NonRefundableLicenseIssueFee
Namespace Prefix: | LIXT_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Company agreed to pay non-refundable milestone payments which cannot be credited against earned royalties payable by the Company, based on reaching various clinical and commercial milestones. + References No definition available. + Details
Name: | LIXT_PaymentsOnNonrefundableMilestone
Namespace Prefix: | LIXT_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of milestone. + References No definition available. + Details
Name: | LIXT_PercentageOfMilestone
Namespace Prefix: | LIXT_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of proceeds agree to pay under agreement + References No definition available. + Details
Name: | LIXT_PercentageOfProceedsAgreeToPayUnderAgreements
Namespace Prefix: | LIXT_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Reimbursement expense. + References No definition available. + Details
Name: | LIXT_ReimbursementExpense
Namespace Prefix: | LIXT_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of expense for employee benefit and equity-based compensation. + References No definition available. + Details
Name: | us-gaap_EmployeeBenefitsAndShareBasedCompensation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227 + Details
Name: | us-gaap_GeneralAndAdministrativeExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_LossContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions. + References No definition available. + Details
Name: | us-gaap_OtherCommitment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Description of the nature and terms of commitment. + References No definition available. + Details
Name: | us-gaap_OtherCommitmentsDescription
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of cash paid for royalties during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (g) -URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585 + Details
Name: | us-gaap_PaymentsForRoyalties
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 730 -Section 25 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold. + References No definition available. + Details
Name: | us-gaap_SalariesWagesAndOfficersCompensation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details
Name: | us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_GrupoEspanolDeInvestigacionEnSarcomasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_NDAConsultingCorpMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=LIXT_CityOfHopeNationalMedicalCenterMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=LIXT_CollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=LIXT_BioPharmaWorksLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=LIXT_MoffittCancerCenterandResearchInstituteHospitalIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=LIXT_ClinicalTrialAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=LIXT_OtherClinicalAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=LIXT_WorkOrderAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=LIXT_TheradexSystemsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=LIXT_MaterialTransferAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=LIXT_INSERMMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_PlanNameAxis=LIXT_DevelopmentMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_PlanNameAxis=LIXT_CommercialMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=LIXT_ExclusiveLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_VestingAxis=LIXT_FirstFourYearsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_VestingAxis=LIXT_FiveYearsAndThereafterMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=LIXT_EmploymentAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_TitleOfIndividualAxis=LIXT_Dr.JohnKovachMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_TitleOfIndividualAxis=LIXT_Dr.JamesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=LIXT_MasterServiceAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=LIXT_FoundationForAngelmanSyndromeTherapyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=LIXT_ServiceAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=LIXT_IRTHCommunicationsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |